Use of peginterferon alfa-2a (40 KD) (Pegasys®) for the treatment of hepatitis C

Advanced Drug Delivery Reviews

Volumn 54, Issue 4, 2002, Pages 571-586

  Rajender Reddy, K ^a   Modi, Marlene W ^b   Pedder, Simon ^c  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c Shearwater Corporation   (United States)

Author keywords

Chronic hepatitis C; Hepatitis C virus; Interferon; Peginterferon alfa 2a (40 KD); Pegylated interferon; Polyethylene glycol; Ribavirin; Viral hepatitis

Indexed keywords

ABSORPTION; PATIENT TREATMENT; POLYETHYLENE GLYCOLS; PROBABILITY; RNA;

VIROLOGICAL RESPONSES;

DRUG PRODUCTS;

2',5' OLIGOADENYLATE SYNTHETASE; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; REBETRON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ANTIVIRAL ACTIVITY; DRUG ABSORPTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS C; HUMAN; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; VIRUS LOAD;

EID: 0037124508     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-409X(02)00028-5     Document Type: Article

References (58)

1. Pegylation: A novel process for modifying pharmacokinetics
2. A branched methoxy 40 kDa polyethylene glycol (PEG) moiety optimizes the pharmacokinetics (PK) of peginterferon a-2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC)
3. Interferon kinetics and adverse reactions after intravenous, intramuscular, and subcutaneous injection
4. Clinical pharmacokinetics of interferons
5. Influence of human serum albumin content in formulations on the bioequivalency of interferon alfa-2a given by subcutaneous injection in healthy male volunteers
6. The uses and properties of PEG-linked proteins
7. The clinical efficacy of polyethylene glycol-modified proteins
8. The pharmacokinetics of pegylated-40 K interferon alfa-2a (PEG-IFN) in chronic hepatitis C (CHC) patients with cirrhosis
9. Strategies for the preparation and characterization of poly(ethylene glycol) vinyl sulfone
10. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice
11. A branched monomethoxypoly(ethylene glycol) for protein modification
12. Polyethylene glycol-conjugated pharmaceutical proteins
13. Pharmacokinetic properties of five polyethylene glycol conjugates of interferon alfa-2a
14. Rational design of a potent, long-lasting form of interferon: A 40kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C
15. Positional isomers of monopegylated interferon alpha-2a: Isolation, characterization, and biological activity
16. Consensus Statement
17. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium
18. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related disease
19. Statement: Management of hepatitis C
20. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994
21. Projecting the future healthcare burden from hepatitis C in the United States
22. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: A comparison
23. Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT
24. Factors predictive of a beneficial response to therapy of hepatitis C
25. Early predictors of response to treatment in patients with chronic hepatitis C
26. Single-dose safety/tolerability and pharmacokinetic/pharmacodynamics (PK/PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon α-2a (IFN α-2a) to healthy subjects
27. The pharmacokinetic behavior of pegylated (40 kDa) interferon alfa-2a (PEGASYS) in chronic hepatitis C patients after multiple dosing
28. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects
29. Clearance of pegylated (40 kDa) interferon alfa-2a (PEGASYS) is primarily hepatic
30. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C
31. Peginterferon alfa-2a in patients with chronic hepatitis C
32. Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group
33. Superior virological response in genotype 4 chronic hepatitis C patients treated with pegylated (40 kDa) interferon alfa-2a (Pegasys) compared with standard interferon
34. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis
35. Efficacy of pegylated (40 kDa) interferon alfa-2a (Pegasys) in randomized trials of patients with chronic hepatitis C, with and without cirrhosis: Correlation of virological and histological responses with baseline liver histology and genotype
36. Histological improvement to pegylated interferon alfa-2a or standard interferon alfa-2a: A randomized, multinational trial in hepatitis C patients with compensated cirrhosis or bridging fibrosis
37. Pegylated (40 kDa) IFN alfa-2a (PEGASYS) is superior to IFN alfa-2a (ROFERON-A) in improving post-treatment histological outcome in chronic hepatitis C patients
38. Design of the HALT-C trial (hepatitis C antiviral long-term treatment to prevent cirrhosis)
39. Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon alfa-2a
40. Rapid viral response to treatment with pegylated (40 kDa) interferon alfa-2a (PEGASYS) is strongly predictive of a sustained virological response in patients with chronic hepatitis C (CHC)
41. Prognostic factors and early predictability of sustained viral response (SVR) in patients treated with pegylated (40 kDa) interferon alfa-2a (PEGASYS): A new profile
42. Improved work productivity, safety, and quality of life with pegylated (40 kDa) interferon alfa-2a (PEGASYS) therapy in the treatment of chronic hepatitis C
43. Therapy with pegylated (40 kDa) interferon alfa-2a (PEGASYS) significantly enhances quality of life compared with standard interferon alfa-2a (ROFERON-A) in patients with chronic hepatitis C
44. The effect of successful anti-viral therapy on health-related quality of life for patients with chronic hepatitis C and cirrhosis
45. Combination therapy with peginterferon alfa-2a (Pegasys) and ribavirin in the treatment of patients with chronic hepatitis C: A phase II open-label study
46. Pegylated interferon alfa-2a (Pegasys) in combination with ribavirin: Efficacy and safety results from a phase III, randomized, actively controlled, multicenter study
47. PEG-Interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety and preliminary efficacy data
48. A pharmacokinetic model for alpha interferon administered subcutaneously
49. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
50. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
51. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus
52. A randomised, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C
53. Evaluation of two doses of peginterferon alfa-2a for the treatment of chronic hepatitis C (CHC)